Arrowhead Pharmaceuticals (ARWR) is back in focus after fresh regulatory approvals for REDEMPLO in China and Canada, along ...

Arrowhead Pharmaceutical’s investigational RNA interference (RNAi) obesity candidate in combination with Eli Lilly’s Zepbound ...

Patients receiving concomitant PCSK9 inhibitor therapy experienced greater LDL cholesterol reductions, exceeding 50% during ...

Arrowhead Pharmaceuticals today announced interim results from two Phase I/IIa clinical trials of ARO-INHBE and ARO-ALK7, the ...

Transverse tubules (T-tubules) play a significant role in muscle contraction. However, the underlying mechanism of their ...

Arrowhead Pharmaceuticals reported early trial data showing notable reductions in body, liver, and visceral fat from two experimental obesity drugs, with more results expected in 2026.

Arrowhead Pharmaceuticals, Inc. today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics being ...

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

Netherlands-based Scenic Biotech, a company advancing modifier therapy—a radical new approach to treating genetic ...

Viruses occupy a central place in ecology and health, influencing the dynamics of terrestrial, aquatic, and managed ...

A live webcast of the presentation can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.